Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma

Annals of Surgery

Volumn 247, Issue 4, 2008, Pages 687-693

  Guggenheim, Merlin M ^a   Hug, Urs ^a   Jung, Florian J ^a   Rousson, Valentin ^b   Aust, Matthias C ^c   Calcagni, Maurizio ^a   Künzi, Walter ^a   Giovanoli, Pietro ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; CANCER CONTROL; CANCER RECURRENCE; CANCER SURVIVAL; CERVICAL LYMPH NODE; CLINICAL OBSERVATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; HOSPITAL READMISSION; HUMAN; INGUINAL LYMPH NODE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; MORBIDITY; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; MALE; MELANOMA; MIDDLE AGED; MORBIDITY; RECURRENCE; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 41149124822     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318161312a     Document Type: Article

References (59)

1. Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg. 1999;230:453-463.
2. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634.
3. Cochran AJ, Balda BR, Starz H, et al. The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer. 2000;89:236-241.
4. Wrightson WR, Wong SL, Edwards MJ, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol. 2003;10:676-680.
5. Gutzmer R, Al Ghazal M, Geerlings H, et al. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients. Br J Dermatol. 2005;153:1137-1141.
6. Lens MB, Dawes M, Goodacre T, et al. Excision margins in the treatment of primary cutaneous melanoma. A systemic review of randomized controlled trials comparing narrow vs. wide excision. Arch Surg. 2002;137:1101-1105.
7. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242:302-311.
8. Dummer R, Panizzon R, Bloch PH, et al. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology. 2005;210:39-44.
9. Karakousis CP, Hena MA, Emrich LJ, et al. Axillary node dissection in malignant melanoma: results and complications. Surgery. 1990;108:10-17.
10. Urist MM, Maddox WA, Kennedy JE, et al. Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients. Cancer. 1983;51:2152-2156.
11. Hughes TMD, A'Hern RP, Thomas JM. Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma. Br J Surg. 2000;87:892-901.
12. Serpell JW, Carne PWG, Bailey M. Radical lymph node dissection for melanoma. ANZ J Surg. 2003;73:294-299.
13. Beitsch P, Balch C. Operative morbidity and risk factor assessment in melanoma patients undergoing inguinal lymph node dissection. Am J Surg. 1992;164:462-465; discussion 465-466.
14. Karakousis CP. Therapeutic node dissections in malignant melanoma. Ann Surg Oncol. 1998;5:473-482.
15. Shaw JH, Rumball EM. Complications and local recurrence following lymphadenectomy. Br J Surg. 1990;77:760-764.
16. McMasters KM, Noyes RD, Reintgen DS, et al. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol. 2004;86:212-223.
17. De Vries M, Vonkeman WG, van Ginkel RJ, et al. Morbidity after inguinal sentinel lymph node biopsy and completion lymph node dissection in patients with cutaneous melanoma. Eur J Surg Oncol. 2006;32:785-789.
18. Baas PC, Schraffordt Koops H, Hoekstra HJ, et al. Groin dissection in the treatment of lower-extremity melanoma. Short-term and long-term morbidity. Arch Surg. 1992;127:281-286.
19. Karakousis CP, Driscoll DL. Groin dissection in malignant melanoma. Br J Surg. 1994;81:1771-1774.
20. Thompson JF, Waugh RC, Saw RPM, et al. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat. 1994;7:188-192.
21. Hughes TMD, Thomas JM. Combined inguinal and pelvic lymph node dissection for stage II melanoma. Br J Surg. 1999;86:1493-1498.
22. Karakousis CP, Goumas W, Rao U, et al. Axillary node dissection in malignant melanoma. Am J Surg. 1991;162:202-207.
23. De Vries M, Vonkeman WG, van Ginkel RJ, et al. Morbidity after axillary sentinel lymph node biopsy in patients with cutaneous melanoma. Eur J Surg Oncol. 2005;31:778-783.
24. Lawton G, Rasque H, Ariyan S. Preservation of muscle fascia to decrease lymphedema after complete axillary and ilioinguinofemoral lymphadenectomy for melanoma. J Am Coll Surg. 2002;195:339-351.
25. Benoit L, Boichot C, Cheynel N, et al. Preventing lymphedema and morbidity with an omentum flap after ilioinguinal lymph node dissection. Ann Surg Oncol. 2005;12:793-799.
26. Dardarian TS, Gray HJ, Morgan MA, et al. Saphenous vein sparing during inguinal lymphadenectomy to reduce morbidity in patients with vulvar carcinoma. Gynecol Oncol. 2006;101:140-142.
27. Tonouchi H, Ohmori Y, Kobayashi M, et al. Operative morbidity associated with groin dissections. Surg Today. 2004;43:413-418.
28. Judson PL, Jonson AL, Paley PJ, et al. A prospective randomized study analyzing sartorius transposition following inguinal-femoral lymphadenectomy. Gynecol Oncol. 2004;95:226-230.
29. Van Akkooi ACJ, Bouwhuis MG, van Geel AN, et al. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. Eur J Surg Oncol. 2007;33:102-108.
30. Bold RJ, Mansfield PF, Berger DH, et al. Prospective randomized double-blind study of prophylactic antibiotics in axillary lymph node dissection. Am J Surg. 1998;176:239-243.
31. Coit DG, Peters M, Brennan MF. A prospective randomized trial of perioperative cefazolin treatment in axillary and groin dissection. Arch Surg. 1991;126:1366-1371.
32. Clary BM, Mann B, Brady MS, et al. Early recurrence after lymphatic mapping and sentinel node biopsy in patients with primary extremity melanoma: a comparison with elective lymph node dissection. Ann Surg Oncol. 2001;8:328-337.
33. Essner R, Conforti A, Kelley M, et al. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol. 1999;6:442-449.
34. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-1317.
35. Berk DR, Johnson DL, Uzieblo A, et al. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004. Arch Dermatol. 2005;141:1016-1022.
36. O'Brien CJ, Coates AS, Petersen-Schaefer K, et al. Experience with 998 cutaneous melanomas of the head and neck over 30 years. Am J Surg. 1991;162:310-314.
37. Jonk A, Strobbe LJ, Kroon BB, et al. Cervical lymph-node metastasis from cutaneous melanoma of the head and neck: a search for prognostic factors. Eur J Surg Oncol. 1998;24:298-302.
38. Turkula LD, Woods JE. Limited or selective nodal dissection for malignant melanoma of the head and neck. Am J Surg. 1984;148:446-448.
39. Calearo CV, Teatini G. Functional neck dissection: anatomical grounds, surgical technique, clinical observations. Ann Otol Rhinol Laryngol. 1983;92:215-222.
40. Bocca E. Supraglottic laryngectomy and functional neck dissection. J Laryngol Otol. 1966;80:831-838.
41. Van de Vrie W, Eggermont AM, Van Putten WL, et al. Therapeutic lymphadenectomy in melanomas of the head and neck. Head Neck. 1993;15:377-381.
42. Byers RM. Treatment of the neck in melanoma. Otolaryngol Clin North Am. 1998;31:833-839.
43. Byers RM. The role of modified neck dissection in the treatment of cutaneous melanoma of the head and neck. Arch Surg. 1986;121:1338-1341.
44. O'Brien CJ, Petersen-Schaefer K, Ruark D, et al. Radical, modified, and selective neck dissection for cutaneous malignant melanoma. Head Neck. 1995;17:232-241.
45. Mack LA, McKinnon JG. Controversies in the management of metastatic melanoma to regional lymphatic basins. J Surg Oncol. 2004;86:189-199.
46. Fisher SR. Elective, therapeutic and delayed lymph node dissection for malignant melanoma of the head and neck: analysis of 1444 patients from 1970 to 1998. Laryngoscope. 2002;112:99-110.
47. Doting EH, de Vries M, Plukker JT, et al. Does sentinel lymph node biopsy in cutaneous head and neck melanoma alter disease outcome? J Surg Oncol. 2006;93:564-570.
48. Pharis DB. Cutaneous melanoma: therapeutic lymph node and elective lymph node dissections, lymphatic mapping and sentinel lymph node biopsy. Dermatol Ther. 2005;18:397-406.
49. Meyer T, Merkel S, Gohl J, et al. Lymph node dissection for clinically evident lymph node metastases of malignant melanoma. EJSO. 2002;28:424-430.
50. Kretschmer L, Preusser K. Standardized axillary lymphadenectomy improves local control but not survival in patients with palpable lymph node metastases of cutaneous malignant melanoma. Langenbeck Arch Surg. 2001;386:418-425.
51. Chan AR, Essner R, Wanek LA, et al. Judging the therapeutic value of lymph node dissections in melanoma. J Am Coll Surg. 2000;191:16-23.
52. Kretschmer L, Neumann C, Preuber K, et al. Superficial inguinal and radical ilioinguinal lymph node dissection in patients with palpable melanoma metastases to the groin: an analysis of survival and local recurrence. Acta Oncol. 2001;40:72-78.
53. Coit DG, Brennan MF. Extent of lymph node dissection in melanoma of the trunk or lower extremity. Arch Surg. 1989;124:162-166.
54. Mann GB, Coit DG. Does the extent of operation influence the prognosis in patients with melanoma metastatic to inguinal nodes? Ann Surg Oncol. 1999;6:263-271.
55. Meyer T, Möhrle M, Garbe C, et al. Sentinel lymph node in melanoma. Chirurgie. 2004;57:774-780.
56. Stone CA, Goodacre TEE. Surgical management of regional lymph nodes in primary cutaneous malignant melanoma. Br J Surg. 1995;82:1015-1022.
57. Kretschmer L, Neumann C, Marsch WC. In regard to: Lee RJ, et al. Nodal Basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2000;46:467-474.
58. Int J Radiat Oncol Biol Phys. 2000;48:1267-1268.
59. Wong SL, Morton DL, Thompson JF, et al. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol. 2006;13:809-816.